Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact

Tag: Osivax

Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to Its Board of Directors
April 14, 2022 Off

Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to Its Board of Directors

By Author

Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, has appointed Dr. Michael Watson to its Board of Directors.

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Rare Diseases Treatment Market Analysis and Forecast 2025-2032: A $45.8 Billion Opportunity – Complex Challenges and Unprecedented Opportunities are Emerging – ResearchAndMarkets.com

December 19, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine